Affinity 2007 Conference
NYU Kimmel Center, New York, NY
July 8 - 12, 2007

Program and Speaker Biographies (as of June 30, 2007)

Sunday, July 8, 2007
Affinity 2007 Welcoming Reception (5 pm)

6:30 pm to 6:45 pm

George Ehrlich, Hoffmann - La Roche, Nutley, NJ

Keynote Lecture
6:45 pm to 7:45 pm

A Human Protein Atlas Based on Affinity Proteomics
Mathias Uhlén
Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden

Monday, July 9, 2007

Opening Ceremonies
8:45 am to 9:00 am

Richard Willson, University of Houston, Houston, TX

Chairman Introduction
9:00 am to 9:15 am

Session 1:  Affinity:  Past, Present and Future
Mathias Uhlén, Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden

9:15 am - 10:00 am

My Life with Affinity:  Essentials of Biorecognition and its Application
Meir Wilchek
Department of Biological Chemistry, Weizmann Institute of Science, Rehovot, Israel

10:00 am to 10:30 am

Monolith Supports with Affinity and Pseudo Affinity Ligands for Superfast Purification of Biomolecules
M. A. Vijayalakshmi1,2
1Laboratoire d'Interactions Moléculaires et de Technologie de Séparation (LIMTech.S),  Centre de Recherche de Royallieu, BP 20.529, 60205 Compiègne Cedex, France
2Center for BioSeparations Technology, VIT University, Vellore, 632014, India

10:30 am to 10:50 am


10:50 am to 11:20 am

Immunodepletion - What's Beneath the Tip of the Plasma Proteome Iceberg?
Mark S. Baker1,2, Alamgir Khan1, Wai-Kei Shum2, Sock-Hwee Tan2, Veronika Polaskova2 and Amit Kapur2
1Australian Proteome Analysis Facility Ltd (APAF)
2Dept. of Chemistry and Biomolecular Sciences, Macquarie University, 2109. Sydney, Australia

11:20 am to 12:00 pm

The NCI’s Clinical Proteomic Technology Initiative for Cancer - The Reagent Resource Core 
Adam Michael Clark
National Cancer Institute, Office of Technology and Industrial Relations, Bethesda MD

12:00 pm to 1:30 pm

Flexible Formats for Characterizing and Screening Protein-Protein Interactions using Bio Layer Interferometry on the Octet System
Matthew Kirtley
ForteBio, Inc. Menlo Park, CA

Chairman Introduction
1:30 pm to 1:45 pm

Session 2:  Advances in Affinity Technologies
Lars Hagel, GE Healthcare, Uppsala, Sweden

1:45 pm to 2:30 pm

Evolution of Industrial Affinity in Biopharmaceutical Production
Duncan Low
Process Development, Amgen, Inc., Thousand Oaks, CA

2:30 pm to 3:00 pm

Efficiency Improvements in the Discovery and Development of Novel Antibody Format and Protein-Based Biotherapeutics Using CaptureSelect® Affinity Ligands and Yeast Display Discovery Tools
Hendrik Adams and Pim Hermans
BAC bv (The BioAffinity Company), Huizerstraatweg 28, 1411 GP Naarden, Naarden, The Netherlands

3:00 pm to 3:20 pm


3:20 pm to 3:50 pm

Generation of Fully Human Antibodies Derived from Fab-on-phage Display Libraries.  Rapid Kinetic-based Screening of Fab Fragments for Lead Identification
Marc Vanhove
Dyax s.a., Boulevard du Rectorat 27B, Building 22, B-4000 Liege (Sart-Tilman), Belgium

3:50 pm to 4:20 pm

Novel Approaches to Affinity Screening
Enrique Carredano, Katarina Öberg, Tryggve Bergander, Lena Kärf, Charlotte Brink, Kristina Nilsson-Valimaa, Katarina Stenklo, Jan Bergström, Carina Engstrand, Åsa Dahlstedt-Hagman, Niklas Pettersson, Mats Nilsson, Nils Stafström, Karol Lacki, Bo-Lennart Johansson, Jean-Luc Maloisel
GE Healthcare Biosciences AB, Uppsala, Sweden

Award Program
4:30 pm to 6:00 pm

Roche Younger Investigators
A. Cecilia A. Roque, Centro de Química Fina e Biotecnologia, Universidade Nova de Lisboa, Caparica, Portugal

4:35 - 4:50
Development of HIC Media Useful for Isolation of Proteins Carrying Single Amino Acid Substitutions
Kristian Becker*, Elisabeth Hallgren**, Enrique Carredano**, Ronnie Palmgren** and Leif Bülow**
*Department of Pure and Applied Biochemistry, Centre for Chemistry and Chemical Engineering, Lund University Lund, Sweden **GE Healthcare Bio-Sciences AB, Uppsala, Sweden

4:50 - 5:05
Development of New OMNiMIPs (One Monomer Molecularly Imprinted Polymers)
Jason LeJeune and David Spivak
Department of Chemistry, Lousiana State University, Baton Rouge, LA

5:05 - 5:20
Novel Affinity Ligands for the Purification of Antibody Fragments
Jonathan M. Haigh, Christopher R. Lowe
Institute of Biotechnology, University of Cambridge, Cambridge, UK

5:20 - 5:40
Conformational Flexibility and Kinetic Complexity in Antigen-antibody Interactions
Katerina Kourentzi, Mohan Srinivasan, Sandra J. Smith-Gill and Richard C. Willson
Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX USA

5:40 - 6:00
Molecular Imprinted Polymers for Selective Protein Adsorption by Miniemulsion Polymerization
Marc Herold, Klaus Niedergall, Melanie Dettling, Yunxiao Wang, Guenter Tovar
Fraunhofer-Institute for Interfacial Engineering and Biotechnology & Institute for Interfacial Engineering, University of Stuttgart, Stuttgart, Germany

Day Break
6:00 pm to 8:00 pm

ISMR Council Meeting/Posters/Exhibits

Tuesday, July 10, 2007

Chairman Introduction
8:45 am to 9:00 am

Session 3:  New Developments in Chromatography
Juan A. Asenjo, Department of Chemical Engineering and Biotechnology, University of Chile, Santiago, Chile

9:00 am to 9:45 am

Mathematical Modeling of Elution Curves for a Protein Mixture in Chromatography Applied to the Optimal Selection of Operating Conditions
J. A. Asenjo and B.A. Andrews
Department of Chemical Engineering and Biotechnology, University of Chile, Santiago, Chile

9:45 - 10:15 am

Affinity Interaction under Chaotropic Conditions
Rainer Hahn1,2, Waltraud Kaar2, Barbara Kanatschnig1, Sabine Geinstetter1, Karin Ahrer1,2 and Alois Jungbauer1,2
1Austrian Center of Biopharmaceutical Technology, Muthgasse 18, 1190 Vienna, Austria
2Department of Biotechnology, University of Natural Resources and Applied Life Sciences, Vienna, Muthgasse 18, 1190 Vienna, Austria

10:15 am to 10:35 am


10:35 am to 11:05 am

ImmunoAffinity Capillary Electrophoresis for the Identification and Characterization of Toxic Biomarkers
Norberto A. Guzman
Johnson and Johnson Pharmaceutical R&D, Global Preclinical Division, Raritan, NJ

11:05 am to 11:35 am

Biacore Applications for Effective Bio-therapeutic Development
Brian Lang1 and Fredrik Sundberg2
1Biacore, Inc. part of GE Healthcare, 800 Centennial Ave., Piscataway, NJ 08854
2GE Healthcare Life Sciences, Rapsgatan 7, 75450 Uppsala, Sweden

11:45 am to 1:15 pm

Success Story of MabSelect
Victor Bornsztejn
GE Healthcare, 800 Centennial Ave., Piscataway, NJ 08854

Poster/Exhibitor Session
1:15 pm to 2:15 pm

Please stand by your poster/exhibit

Chairman Introduction
2:15 pm to 2:30 pm

Session 4:  Nano/Bio/Materials
Richard Willson, University of Houston, Houston TX

Pierce Award Lecture
2:30 pm to 3:15 pm

Molecular Recognition of Proteins on Surfaces and the Development of Critical Hydrophobicity HIC
Herbert P. Jennissen
Institut für physiologsiche Chemie, Universität-Duisburg-Essen, Hufelandstr. 55, D-45122 Essen, Germany

3:15 pm to 3:45 pm

Analyte-Responsive Retro-reflectors for Biochemical Assays and Diagnostics
P. Ruchhoeft, K. Han, A. Ruiz, V. Parekh, W. Xu, D. Litvinov, and S. Chellam
University of Houston, Houston, TX USA 77204

3:45 pm to 4:05 pm


4:05 pm to 4:35 pm

Gold Nanorod Substrates for Localized Surface Plasmon Resonance Sensing
Jason H. Hafner, Kathryn M. Mayer, Seunghyun Lee, Hongwei Liao, Betty C. Rostro, Peter T. Scully
Department of Physics & Astronomy, Department of Chemistry, Rice University, Houston, TX USA 77005

4:35 pm to 5:05 pm

Discovery and Development of OMNiMIPs: One MoNomer Molecularly Imprinted Polymers
David Spivak
Department of Chemistry, Louisiana State University, Baton Rouge, LA

Panel Discussion
5:05 pm to 6:00 pm

Trends in Label-free Interaction Analysis
Ashique Rafique, Regeneron Pharmaceuticals, Tarrytown, NY
Matthew Kirtley (ForteBio), Brian Lang (GE Healthcare), Voula Kodoyianni (GWC Technologies)

Day Break
6:00 pm to 8:00 pm

Posters/Exhibits/Dinner on your own

Wednesday, July 11, 2007

Chairman Introduction
8:45 am to 9:00 am

Session 5:  Insights into Intra- and Inter- Molecular Recognition
M.A.Vijayalakshmi, CBST, VIT University, TamilNadu, India

9:00 am to 9:45 am

Self-Assembly of Soft Molecular Networks: Crystal Design and Curvature
Michael Ward
Molecular Design Institute, Dept. of Chemistry, New York University, New YorkNY

9:45 - 10:15 am

Molecular Recognition of Foreign Sequences in Engineered 5S Ribosomal RNA
Xing Zhang1, Ajish S. R. Potty2, George W. Jackson2, George E. Fox1, and Richard C. Willson1, 2
Department of Biology and Biochemistry1 and Department of Chemical Engineering2, University of Houston

10:15 am to 10:35 am


10:35 am to 11:05 am

Small-molecule-mediated Rescue of Protein Function by an Inducible Proteolytic Shunt
Matthew Pratt and Tom Muir
Laboratory of Synthetic Protein Chemistry, The Rockefeller University, 1230 York Avenue, New York, NY 10021

Social Event
11:05 am to 1:30 pm

Walking Tour of the Village featuring Arthur Marks
Posters/Exhibits/Lunch on your own

Chairman Introduction
1:30 pm to 1:45 pm

Session 6:  Protein Interactions In and On Cells
Irwin Chaiken, Drexel UniversityPhiladelphia, PA

1:45 pm to 2:30 pm

Dynamic Visualization of Signaling Activities in Living Cells
Jin Zhang
Depts. Pharmacology/Molecular Sciences and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD

2:30 pm to 3:00 pm

Structure and Function of Eukaryotic RNA Exosomes
C.D. Lima, Q. Liu, J.C. Greimann
Program in Structural Biology, Sloan-Kettering Institute, New York, NY 10021 USA

3:00 pm to 3:20 pm


3:20 pm to 3:50 pm

Electrophoretic Fingerprinting of HIV-1 Cell Interaction: a Novel Tool for Development of Charge-Based Strategies
Fairhurst, D.1, Rowell, R.2, Monahan, I.3, Stieh, D.3, McNeil-Watson, F.4, Morfesis, A.4, Romano, J.1, Shattock, RJ.3 and M. Mitchnick5
1International Partnership for Microbicides, Silver Spring, USA,
2University of Massachusetts, Amherst, USA,
3St. Georges Hospital Medical School, London, UK,
4Malvern Instruments Ltd., Malvern, UK,
5Particle Sciences Inc., Bethlehem, USA

Session 6 Overview
3:50 pm - 4:20 pm

Irwin Chaiken, Drexel UniversityPhiladelphia, PA

Poster/Exhibitor Session
4:20 pm to 5:20 pm

Please stand by your poster/exhibit

Social Event
6:15 pm

Gala Dinner Cruise on New York Harbor

Thursday, July 12, 2007

Chairman Introduction
8:45 am to 9:00 am

Session 7:  Viruses and Vaccines
Daniel Malamud, New York University Dental Center, New York, NY

9:00 am to 9:45 am

Ligand Recognition and Plasticity in HIV Envelope Glycoprotein gp120
Wayne A. Hendrickson1,2, Hui Xie2,3, Anil Korkut2, Danny Ng4 and Amos B. Smith, III4
1Howard Hughes Medical Institute, 2Department of Biochemistry and Molecular Biophysics, and 3Department of Pharmacology, Columbia University, New York, NY 10032 USA
4Department of Chemistry, University of Pennsylvania, Philadelphia, PA 19104 USA

9:45 - 10:30 am

The Role of Antibodies in Preventing and Treating HIV Infection
Susan Zolla-Pazner
New York VA and NYU Medical Centers, New York, NY

10:30 am to 10:50 am


10:50 am to 11:20 am

Biomolecule Recognition in Piezoelectric Immunosensors: Application of Piezoimmunosensors for Detection of HIV1 Virion Infectivity Factor
Guilherme N.M. Ferreira1*, João M. Encarnação1, Luis Rosa1, Rogério Rodrigues1, Luisa Pedro1, Frederico Aires da Silva2, João Gonçalves2
1IBB-Institute for Biotechnology and Bioengineering, Centro de Biomedicina Molecular e Estrutural, Universidade do Algarve, 8000 Faro, Portugal
2URIA-Centro de Patógenese Molecular, Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal

11:20 am to 11:50 am

Interaction of gp340, a Glycoprotein in the Innate Immune System, with HIV-1 env
Daniel Malamud
New York University Dental Center, New York, NY

ISMR General Meeting
11:50 am to 12:15 pm

Presidential Announcements

Lunch Break
12:15 am to 1:15 pm

Posters/Exhibits/Lunch on your own

Chairman Introduction
1:15 pm to 1:30 pm

Session 8:  Drug Discovery and Diagnostics
Waseem Malick and Hitesh Chokshi, Hoffmann - La Roche, Nutley NJ

1:30 pm to 2:15 pm

The Economics of Personalized Medicine: Optimizing Incentives for Innovation
M. J. Finley Austin
Hoffmann - La Roche, Basel, Switzerland and Nutley, NJ

2:15 pm to 2:45 pm

Biomimetic and Supramolecular Scaffolds for Multivalent Display
Kent Kirshenbaum
Department of Chemistry, New York University New York, NY

2:45 pm to 3:15 pm

Designing for Success: The Generation of Useful Leads with Small Molecule Libraries
Robert A. Goodnow Jr.
Discovery Chemistry, Hoffmann-La Roche, Inc., Nutley, NJ

3:15 pm to 4:00 pm

Cancer Chemotherapy with an FDA Approved Transition State Analog Enzyme Binder
Ronald Breslow
Department of Chemistry, Columbia University, New York, NY

Closing Remarks
4:00 pm to 4:30 pm

Affinity 2009: the 18th Biennial Meeting of the International Society for Molecular Recognition
Hordur Filippusson, Organizer and Gidi Fleminger, ISMR President Elect
Summer 2009 Reykajvik, Iceland

Speaker Biographies

Mathias Uhlén

Mathias Uhlén is Professor of Microbiology at the Royal Institute of Technology (KTH), Stockholm, Sweden. Dr Uhlén is member of the Royal Swedish Academy of Engineering Science (IVA), the Royal Swedish Academy of Science (KVA) and the European Molecular Biology Organization (EMBO). He is Vice-President of the European Proteomics Association (EuPA) and member of the Human Proteome Organization (HUPO) council. He was Vice-President of the Royal Institute of Technology (KTH), responsible for external relations, from 1999 to 2001 and he was the chairman of the Swedish Biochemical and Molecular Biology Society (SFMB) from 1994 to 1999. Dr Uhlén has more than 280 publications in bioscience with the focus on the development and use of affinity reagents in biotechnology and biomedicine.

In the early eighties, Dr Uhlén cloned and characterized staphylococcal protein A, which is now used extensively for purification of antibodies both in diagnostics and therapy. He showed in 1983, for the first time, the principle of affinity capture of fusion proteins. The use of affinity tags for purification of recombinant proteins are now widely used in bioscience. In the late eighties, Uhlén published the use of magnetic micro spheres with streptavidin for automated solid phase applications. Such laboratory systems based on streptavidin beads are at present frequently used both in research and diagnostics. In the 90’ies, his group described a new principle for affinity reagents, called Affibodies, and showed their use as research tool and recently as potential cancer therapeutics. Uhlen and colleagues also developed a new strategy for DNA analysis called Pyrosequencing, a method that has recently been further developed by a US company (454) into a highly parallelized sequencing instrument.

Dr Uhlén is currently working on the Human Protein Atlas (HPA) program, with the aim to systematically map the human proteome. In October 2006, version 2.0 of the Protein Atlas was published ( with more than 1.2 million high-resolution images representing 1,359 human proteins. He has founded several companies, including Pyrosequencing AB (Biotage AB), Affibody AB, SweTreeGenomics AB, Magnetic Biosolutions AB, Creative Peptides AB and Atlas Antibodies AB. He has received numerous awards, including The Svedberg prize in 1992, the Göran Gustavsson prize in 1993, the gold medal of the Royal Swedish Academy of Engineering Sciences in 2004, the Most Noble Order of the Seraphim - the Order of His Majesty the King in 2004, the Jerker Porath award and the Akzo Nobel Award in 2005 and the HUPO Distinguished Achievement Award in 2006.

Meir Wilchek

Professor Meir Wilchek has always worked in the interface between organic chemistry and biology, played a pivotal role in the use of the principles of organic chemistry (known today and chemical genetics) for the understanding of biological processes and the establishment of the modern-day concept of biorecognition and its development for the myriads of applications in the various fields of modern biology. This concept and the associated processes, which Meir Wilchek has designed, have had a profound effect on research, industry, medicine, molecular biology, and, consequently, on the human condition in general. In view of the inherent clinical and medical implications of Dr. Wilchek's discoveries, it should come as no surprise that among the list of prizes he has already received, which include the prestigious Wolf Prize, the Israel Prize, and the Pierce Prize, he was elected to the Institute of Medicine of the National Academy of Science, USA. 

Meir Wilchek's studies have been directed towards the understanding and application of the biorecognition phenomenon using chemical methods, and his major contributions have been directed in four different but related aspects: namely, affinity chromatography, affinity labeling, affinity therapy and avidin-biotin technology. Historically, the contribution for which he is best known and for which he has received the most internationally acclaimed awards and honors is the field of affinity chromatography and the avidin-biotin system. In addition, his contributions to the other above-mentioned fields have been of critical scientific impact. In all the above fields, in which he was among the founders, he had to device chemical methods to immobilize, derivatize biological active molecules, such as protein, nucleic acid and even whole cells. All these methods are widely used all over the world.

Adam Michael Clark

Dr. Clark serves as the Program Officer for the Clinical Proteomic Technologies Initiative for Cancer (CPTI) and the Mouse Proteomic Technologies Initiative at the National Cancer Institute. In this role, Dr. Clark oversees the management and operations of the various programs within the initiatives and works to integrate the developing proteomic technologies for application in clinical settings. He also narrates the Clinical Proteomic Technologies tutorial on the CPTI website. His work at the NCI is focused on improving clinical research technologies so that molecular-based medicine approaches can be applied in a clinical setting to make personalized medicine and targeted therapeutics common in medical practice.

Dr. Clark has a background in both medical science research and health policy. Dr. Clark has served as both a researcher and a program administrator for the National Cancer Institute.  In addition to his work with the CPTI, Dr. Clark served as the Life Science Policy Analyst at the White House's Office of Science and Technology Policy working on a variety of issues including overweight/obesity health issues and strategies, stem cell research, and cancer imaging technologies. Dr. Clark also served as the science policy advisor for the Deputy Chief of Staff in the Office of the Secretary, Department of Health and Human Services working on several key projects in the Department including the 2005 Dietary Guidelines for Americans. Dr. Clark returned to the NCI Office of Technology and Industrial Relations in 2005.

Dr. Clark has a Ph.D. in Environmental Health from the University of Cincinnati College of Medicine with an emphasis on gene-environment interactions in disease onset and targeted treatment. Dr. Clark's research experience focused on alterations of signal transduction pathways in tumorigenesis. He was enrolled in the Graduate Partnership Program at the National Institutes of Health and was a 2002 recipient of the Cancer Research Training Award from the National Cancer Institute where he completed his graduate studies and postdoctoral work.

Lars Hagel

Lars Hagel is Director of External R&D Collaborations at GE Healthcare Bio-Sciences AB, Uppsala, Sweden and associate professor in analytical chemistry at Uppsala University.  He joined Pharmacia in the mid 70'íes and has held scientific and management positions within the R&D departments of Pharmacia Biotech, Amersham Pharmacia Biotech and now GE Healthcare. Lars has authored approximately 30 papers, chapters and textbooks related to chromatography, and in particular to gel filtration. His latest contribution is as co-author to the second edition of Process Chromatography Handbook which will be released in the autumn of 2007. Lars is frequently engaged in the steering of joint efforts and strategic initiatives between academia, industry and society in Sweden. He arranged and was the meeting chairman for Affinity 2005 held in Uppsala, August 2005.

Duncan Low

Duncan Low, Scientific Executive Director, joined the Process Development Department at Amgen in 2003, where he leads cross-functional teams for technology evaluation, technology development and Process Analytical Technology. He is a member of the ISPE Executive Committee for PAT and chairs the ASTM E55.01 subcommittee. Prior to joining Amgen he held senior positions at Millipore and Pharmacia Biotech. He has extensive experience of the tools currently in use in upstream and downstream processing and has worked closely with applications development throughout the industry. He has an M.A. in biochemistry from the University of Cambridge and a Ph.D. in microbiology from the University of Glasgow.

Hendrik Adams

Prior to joining The Bio Affinity Company (BAC) as Ligand Discovery Scientist, Hendrik Adams was a postdoctoral scientist in the Cellular Architecture & Dynamics group of Utrecht University (The Netherlands). In this group, he carried out research for the application of llama antibodies in medical devices. Previously, he was a postdoctoral scientist within a Marie Curie Research Training Network funded by the European Union. In that position, he studied the iron uptake in the opportunistic pathogen Pseudomonas aeruginosa in the department of Receptors and Membrane Proteins at the University of Strasbourg (France). He received his Ph.D. degree in the field of Molecular Microbiology from the Utrecht University.

Mark S. Baker 

Received his BSc Hons 1 in 1981 & PhD in 1985Macquarie University and undertook postdoctoral studies at Monash University, John Curtin School of Medical Research and Howard Hughes Medical Research Institute University of Michigan.  Mark is currently the Chief Executive Officer of a Major National Research Facility called the “Australian Proteome Analysis Facility” and he is also Professor of Proteomics, Dept. Chemistry & Biomolecular Sciences, Macquarie University.

Mark’s previous industry experience is in the development of new biochip platforms (through LumiCyte California, USA).  He was the founder of the Gynaecological Cancer Research Centre, Royal Women’s Hospital, Melbourne, is a Council Member of HUPO and Asia Oceania HUPO as well as Secretary of the Australasian Proteomics Society. Mark is currently a member of the Science Industry Action Agenda Leader’s Group. He won the 1994 Sports Medicine Australia Order of Fellows, the 1991 Howard Florey Young Investigator Medal and the 1988 & 1990 International Young Investigator Awards from the Society for Free Radical Research. He has over 80 publications, 3 patents, has trained ~20 PhD students and ~30 BSc(Hons)/BBiotech students. 

Mark’s interests are in biomarker discovery, proteomic technologies, research commercialisation, building the Australian biotech sector and Rugby. He holds grants with proteomics industry leaders (eg. GE Healthcare, QIAGEN, Applied Biosystems) and has most recently developed novel immunodepletion strategies using chicken eggs.

Enrique Carredano

Dr. Enrique Carredano holds a Degree of Doctor of Technology from the Swedish University of Agricultural Sciences in the area of Structural Molecular Biology (x-ray protein crystallography). From June 1999 he has been working as a scientist at GE Healthcare Biosciences AB in Uppsala, contributing to research and development projects with molecular modeling expertise within the area of modeling affinity and ion-exchange interactions for chromatography. His most recent area of focus has been in the implementation of robot applications for high throughput screening of chromatographic parameters for process development.

Juan Asenjo

Juan A. Asenjo de Leuze is a chemical engineer from the University of Chile and he obtained his PhD from University College London in 1978. He obtained the National Science Prize in 2004. His research work in the Biotechnology field is shown by 160 international scientific publications, 4 international patents and 4 books edited. He has supervised a large number of PhD students (41) in the USA, England and Chile and has had 11 postdoctoral fellows. He was Associate Professor and Director of the Biochemical Engineering Laboratory at Columbia University (New York, 1980-1986) and created such a laboratory in the University of Reading (Reader) in England (1986-1994). He is a member of the Editorial Committee of 6 international scientific journals in biotechnology and bioengineering, Vice President of the Chilean Academy of Sciences (and Foreign Officer) and the only engineer ever to obtain a Presidential Chair in Sciences (1997).

Rainer Hahn

Rainer Hahn received a Ph.D. in Biotechnology at the Department of Biotechnology at the University of Natural Resources and Applied Life Sciences in Vienna. In his doctoral thesis he characterized the performance of continuous stationary phases (monolithic media) and developed a novel method for their preparation. His general field of research activity is Downstream processing of biomolecules, in particular preparative chromatography. One of his main research areas is the screening of peptides from combinatorial libraries designed as ligands for affinity chromatography. He conducted several benchmark studies comparing commercial chromatography media, namely HIC, hydroxyapatite and Protein A affinity sorbents. Currently he works as a research assistant in the Austrian Center of Biopharmaceutical Technology (ACBT), a technology platform of two university departments and the biopharmaceutical companies Boehringer Ingelheim Austria and Sandoz. The focus of his current work is the development of novel refolding techniques with special interest on matrix-assisted refolding techniques.

A. Cecilia Roque

Cecília Roque is an Assistant Professor and Researcher at the Faculty of Sciences and Technology in Lisbon. Cecília obtained a degree in Chemical Engineering (Biotechnology specialization) in 1999 and a PhD in Biotechnology in 2004 by Instituto Superior Técnico ( Portugal) in collaboration with the University of Cambridge (UK). She has been a visiting scholar, supervisor of students and a post-doc researcher at the Institute of Biotechnology, University of Cambridge (UK) between 1999 and 2005.

Fredrik Sundberg

As Director of Market Development for the pharmaceutical and biotech industrial sector, Mr. Sundberg is responsible for expanding the application of label free interaction analysis throughout drug discovery and development, in-process and quality control workflows. He advises on in-house development projects and has specialist knowledge in the area of validation support and frequently provides GxP (GLP, GCP, GMP) training to the pharmaceutical industry. He has conducted several pharmaceutical development projects, completed validation studies for a variety of analytical instruments and process equipment, and produced more than 100 IQ/OQ/PQs for different pharmaceutical companies worldwide. Mr. Sundberg is the author of several publications and articles in the field of using biosensor technology for productivity improvements and GxP quality control. During the past several years, Fredrik has presented at numerous premier conferences globally. On a regular basis, he lectures and discusses regulatory issues with organizations from both industrial and government authorities and advises on in-house development projects.

Paul Ruchhoeft

Dr. Paul Ruchhoeft is an Assistant Professor of Electrical and Computer Engineering at the University of Houston and is the author of over 20 archival publications ranging from the fundamentals to applications of nanolithography. His research interests include micro-and nano-fabrication using ion beam proximity lithography, thin-film deposition and etching, development of retroreflector-based diagnostic tools, and the modeling of resist exposure and development.

Jason Hafner

Jason H. Hafner received his B.S. degree in Physics from Trinity University in 1993 and his Ph.D. from Rice University in 1998 under Richard E. Smalley.  He was an NIH postdoctoral fellow in the Department of Chemistry and Chemical Biology at Harvard University from 1998 to 2001 working in the lab of Professor Charles M. Lieber.  Hafner returned to Rice in 2001 as an Assistant Professor in the Department of Physics & Astronomy, and holds a joint appointment in the Department of Chemistry.  He was named a Beckman Young Investigator by the Beckman Foundation in 2002 and has served as the Associate Director of the Laboratory for Nanophotonics at Rice since 2005.  His research interests include applications of atomic force microscopy and nanophotonics to fundamental and applied areas of membrane biophysics and biomolecular interactions.

David Spivak

David Spivak received his B.S. degree in Chemistry from UC Berkeley in 1989, and his Ph.D. degree in Polymer/Organic Chemistry from UC Irvine in 1995, under the direction of Professor Ken Shea.  He then was awarded an NIH Post-Doctoral Fellowship for his proposal to study catalytic antibodies for polymerization and other reactions at The Scripps Research Institute from 1995 to 1998.  Afterward he began his professional career at Louisiana State University (LSU) in Baton Rouge, where he presently resides as an Associate Professor of Chemistry.  Research in the Spivak Group is multidisciplinary, focused on Molecularly Imprinted materials, thin films and nanoparticles for biological and environmental analysis.  In addition to research funding from NIH and NSF, including an NSF-CAREER award, Professor Spivak has received teaching awards from Research Corporation (Cottrell Scholar), and LSU (The LSU Athletic Foundation Undergraduate Teaching Award for 2001).  He is also an Associate Editor for the Journal of Molecular Recognition. 

Michael Ward

Professor Ward attended William Paterson College and graduated in 1977 with a Bachelor of Arts degree in Chemistry. He received a Ph.D. in Chemistry from Princeton University in 1981. His thesis research, under the mentorship of Professor Jeffrey Schwartz, was on the "Investigation of Oxide Bound Transition Metal Complexes." Upon his graduation, he worked as a Robert A. Welch Postdoctoral Fellow with Professor Allen J. Bard at the University of Texas (Austin) to investigate the fundamentals of semiconductor particles.

From 1982 to 1984, Mike was a Project Leader at the Standard Oil Company of Ohio.  From there, he moved on to work in Central R&D at E.I. duPont de Nemours and Co as a Research Scientist.  In 1990 he joined the faculty at the University of Minnesota, where he held the positions of Distinguished McKnight University Professor and Director of the NSF-funded Materials Research Science and Engineering Center in the Department of Chemical Engineering and Materials Science.

In 2006, he assumed his current position at New York University as Director of the Molecular Design Institute and Professor of Chemistry, where he continues as an Editor of the ACS journal, Chemistry of Materials.  One of his principal research interests is in the area of the design, synthesis and crystal growth of crystalline molecular solids in which the molecules are held together in a lattice by weak, and often unpredictable, intermolecular interactions. 

M.A. Vijayalakshmi

Viji is Professor in the Department of Bioengineering and Director of the Molecular Interaction and Separation Technology   Laboratories at the Université de Technologie de Compiègne.  She is also Director of the Centre for BioSeparation Technology at the Vellore Insitute of Technology at VIT University.

Viji received her Doctorat D'Etat es Science (D. SC) on the topic of Affinity Chromotography And Molecular Interactions in June 1980 from the Universite De Technologie de Compiegne, France.  She received her M.Sc. in March 1966 from All India Institute of Chemistry in Calcutta, India.  Between 1977 and1982, she spent a few months/year as a Research Fellow in the Institute of Biochemistry at Uppsala University in Sweden

She became Distinguished Professor at Universite de Technologie de Compiegne, France in 2001, which is the highest level achievable in the academic career in France.  Her other responsibilities and credits include:  Coordinator: BioIndustry, International programmes of ARIEL (Association for Research with Industry and Education Links) under the Confederation of Engineering schools, (C G.E.) France, Consultant and Advisor to Council for Scientific and Industrial Research (CSIR) New Delhi, India and President of the International Society for Molecular Recognition (regd USA) from 1994-1997.  She has also served the EU commission in the Ressources Developement (5th and 6th PCRD and as a member of the "Board of Regents of Univ. Technol. de Compiegne” (1997- 2001).  Since 1981, Prof. M.A. Vijayalakshmi at LIMTechS has guided 40 students through their Doctorates, all of whom are pursuing successful scientific careers in academia and industry in both France and the US

She was appointed as Member of the "Standing Advisory Council-Overseas" to the Secretary of State in the Ministry of Science and Technology, India. 1997.  This is the first time that a scientist based in France and a woman was nominated to this committee.

In July 1999, she was awarded the Prestigious Pierce Award for the outstanding achievements in the field of Affinity Technology and Bio Recognition at the International level.

She was conferred the Title of "CHEVALIER de Honor des Palmes Academiques" by the French Republic President Jacques Chirac, in Oct. 2004

She holds more than 120 publications and 6 patents to her credit, all dealing with pseudo bio specific affinity systems.

About 90 persons from 36 different countries have thus benefited from this type of training in her lab, for periods varying from one month to five years.  Under différent exchange programmes, she sends her pupils regularly to many different labs at the international level for short term trainings.

At present she has 20 scientists working in her new Indo-French Excellency Centre in India.  She has an extensive international network and collaborations, including interns, students, junior and senior scientists in exchange/training programmes.

In addition she has served NSF, EU and other international organisations as expert. Her links with industries and academia worldwide make her a good science ambassador.

 Marc Vanhove

Marc Vanhove holds a PhD in Biochemistry (1995) from the University of Liège (Belgium). His doctoral studies aimed at a better understanding of the mechanisms by which b-lactamases fold, i.e. acquire their native, three-dimensional structure. After a short stay at the University of Bayreuth (Germany) where he investigated the early steps of the refolding of his favorite enzymes, Marc received a post-doctoral appointment at the Department of Tumor Cell Biology at St Jude Children’s Research Hospital (Memphis, TN, USA) in 1999 as a fellow of the F.N.R.S., then joined Dyax in 2001 and is now Associate Director of Research.

Matthew Pratt

Matthew Pratt received his BS in biochemistry and mathematics from University of Arizona in 1999.  While an undergraduate, he worked for Prof. Robin Polt on glycosylation methodology and the synthesis of glycosylated analogs of enkephalin.  He then entered the PhD program at the University of California Berkeley under the direction of Prof. Carolyn Bertozzi and received his Ph.D. in 2004.  While in the Bertozzi lab his research focused on the chemical synthesis of glycoproteins and glycopeptide mimetics, developing assays for glycosyltransferase activity and inhibitor screens, and designing chemical tools to understand O-linked glycosylation of proteins.  He is currently an American Cancer Society postdoctoral fellow in the laboratory of Tom Muir at The Rockefeller University in New York.  In the Muir lab, Dr. Pratt’s research has been aimed at both controlling and probing protein function in living cells including the development of a novel methodology for the posttranslational control of protein function called SURF and activity based probes for profiling the caspase family of cysteine proteases.

Irwin Chaiken

Dr. Chaiken attended Brown University and graduated in 1964 with a Bachelor of Arts degree in Chemistry and a minor in Biology.  He received a Ph.D. in Biological Chemistry from University of California at Los Angeles in 1968.

His thesis research, under the mentorship of Prof. Emil Smith, was on "Studies of the Catalytic Center of Papain". He worked as an NIH Postdoctoral Fellow with Dr. Christian Anfinsen on the use of chemical semisynthesis to study structure-function relationships in staphylococcal nuclease.  In 1970, he joined the staff of NIH, first as a Staff Fellow and, starting in 1973, as a Senior Investigator.  In 1988, he moved to SmithKline Beecham, where he served as director of the Macromolecular Sciences Department and then as a Research Fellow in the Molecular Immunology Department of Biopharmaceuticals Research.  In 1995, he moved to University of Pennsylvania, where he became Research Professor of Medicine. He assumed his current position as Professor of Biochemistry and Molecular Biology at Drexel University College of Medicine in February 2003.

Dr. Chaiken's research has been centered in the area of molecular and structural mechanisms of protein recognition and antagonism. His current research projects are focused on receptor interaction mechanisms, including for cytokine receptors in inflammation and HIV-1 envelope complexes in host cell entry; molecular mimicry using protein and miniprotein scaffolds, including design, synthesis and receptor of antagonists for disease treatments; and elucidating molecular recognition mechanisms using biosensors, including development and application of methods for nano and cell sensing studies.

Jin Zheng

Dr. Zhang received her doctoral degree in chemistry from the University of Chicago where she applied chemical approaches to understanding mechanisms underlying bacterial pathogenesis. While a postdoctoral fellow working with Roger Tsien and Susan Taylor, she developed a novel fluorescent sensor, using a generalizable strategy, to visualize the activity of a prototype kinase (Protein Kinase A) in live mammalian cells.

Current topics of interest in her lab at Johns Hopkins include: investigating the spatiotemporal regulation or dysregulation of protein kinases (PKA, Akt/PKB and AMPK) and second messengers in cell migration, energy metabolism and cancer development; developing new technology for multi-dimensional kinase profiling; designing and synthesizing molecular tools for monitoring and perturbing second messenger dynamics in live cells; mechanistic computational modeling and systems analyses of signaling networks; and developing live-cell high-throughput screening methods for identifying kinase regulators.

Christopher D. Lima

Christopher D. Lima received his PhD from Northwestern University in 1994 for work on the structure determination and characterization of E. coli Topoisomerase I, work was completed in the laboratory of Dr. Alfonso Mondragon in collaboration with Dr. James Wang.  In 1995, Dr. Lima joined the laboratory of Dr. Wayne A. Hendrickson as a Helen Hay Whitney Fellow where he characterized the biochemical and structural basis for HIT nucleotidyl transferase family, members of which include aprataxin and FHIT. In the fall of 1998, Dr. Lima joined the faculty at the Weill Medical College of Cornell University as an Assistant Professor. In 2002 he was promoted to Associate Professor and in 2003, Dr. Lima moved his laboratory to the Sloan-Kettering Institute where he is now an Associate Member within the Structural Biology Program. During this period, Dr. Lima has received the Louise and Allston Boyer Young Investigator Award, Mayor's Award for Excellence in Science and Technology, Beckman Young Investigator Award, Dorothy Rodbell Cohen Foundation Award for Sarcoma Research. He was also named a Rita Allen Scholar. Since starting his lab, Dr. Lima’s research has focused in two principle areas of biology, post-translation protein modification by the ubiquitin-like modifier SUMO, and on RNA processing, 5’ cap formation, and RNA decay.

David Fairhurst

Dr. David Fairhurst is a consulting advisor on microbicide formulations (semisolids, films, tablets, rings) to the International Partnership for Microbicides.

Dr. Fairhurst was, formerly, Executive Vice President/Chief Technology Officer with Particle Sciences/ NPR Healthcare Inc. Particle Sciences is a CRO that specializes in controlled drug delivery. NPR manufactures skin-care products targeted specifically for dermatologists, plastic surgeons and aestheticians. He headed the team that invented some of today’s most innovative ingredients for sunprotection, including Z-COTEÔ a transparent zinc oxide voted by Forbes magazine as one of the top ten nanotechnology products in 2003 and SunCapsÔ (encapsulated actives).  Dr. Fairhurst was directly involved in discussions with the FDA to have zinc oxide included in the Final Monograph on Sunscreens, and labeled as a Category I sunscreen active. He has been personally involved in the formulation of hundreds of skin, diaper, eye and lip products.

Dr. Fairhurst received his Ph.D. in Physical Chemistry in 1968 from Liverpool Polytechnic, UK, where he was also a Lecturer (in Physical Chemistry) for four years.  He spent two years as a Visiting Associate Professor in the Center for Surface and Coatings Research at Lehigh University and subsequently held senior research positions with the UK Chemical Defence Establishment, Porton Down (where he authored the 1977 UK Position Paper on Chemical Defence) and with Union Carbide Corporation, USA (where invented enabling silane-coating technology for personal care).  The work encompassed exploratory and basic research, product formulations and development and technical services.

Dr Fairhurst has over 40 years experience in the practical application of colloid and surface chemistry and dispersion/emulsion technology.  He has authored 25 Confidential Business Reports and Classified Government Documents, is entitled to four patents and has published 100 technical papers, scientific articles and book chapters in the open literature.  David is a member of various professional societies in both the USA and the UK.  Elected to Sigma Xi in 1970, he is also a Chartered Scientist (EU) and a Chartered Chemist (UK).  

Wayne Hendrickson

Dr. Wayne A. Hendrickson is a University Professor at Columbia University and an Investigator with the Howard Hughes Medical Institute.  He has a B.A. from the University of Wisconsin at River Falls and a Ph.D. in biophysics from Johns Hopkins University.  His postdoctoral research was with Warner Love at Johns Hopkins and Jerome Karle at the Naval Research Laboratory (NRL).  He remained at NRL as a Research Biophysicist until 1984 when he joined the Department of Biochemistry and Molecular Biophysics at Columbia.

Research in Dr. Hendrickson's laboratory focuses on the structure and function of biological molecules.  He and his colleagues use x-ray crystallography to study molecular properties in atomic detail.  By analyzing x-ray beams diffracted from crystals, they are able to reconstruct images of crystallized molecules.  Their advances in diffraction methods (notably, stereochemically restrained refinement, the multiwavelength-anomalous-diffraction (MAD) method, selenomethionyl proteins, and synchrotron instrumentation) have been instrumental in the emergence of structural biology as a major force in modern biology and molecular medicine.  They use this technology themselves in investigations of protein molecules that function at the surfaces of living cells.

Dr. Hendrickson has published numerous research articles and related reviews.  He serves on advisory bodies for various scientific organizations, governmental agencies, scientific journals and biotechnology companies.  He is a founding editor of Current Opinion in Structural Biology and of Structure, and he is a founder of SGX Pharmaceuticals.  His honors include the Aminoff Prize of the Royal Swedish Academy of Sciences, the Gairdner International Award, and the Harvey Prize of the Technion – Israel Institute of Technology.  He is a fellow of the American Academy of Arts and Sciences and a member of the National Academy of Sciences.   

Susan Zolla-Pazner

Susan Zolla-Pazner is a biologist who has devoted her professional life to areas of Immunology where basic research intersects with the needs of modern medicine.  By 1981, Dr. Zolla-Pazner had an established reputation for studying the immune systems of individuals with cancer.  At that time, she was asked to consult on several patients who had an unusual type of tumor.  These patients were the first patients to be seen with a new form of Kaposi's sarcoma, a tumor related to the disease which, only later, became known as AIDS. In the two decades since, Dr. Zolla-Pazner has authored more that 200 scientific papers on AIDS and related illnesses.  She collaborates actively with researchers around the world and has support through the National Institutes of Health, the Department of Veterans Affairs, and the Bill and Melinda Gates Foundation  for her studies to develop an AIDS vaccine and to train students and health care professionals from India, Cameroon and China in the prevention, diagnosis and treatment of AIDS and tuberculosis.

On a personal level, Dr. Zolla-Pazner has been married for 31 years to Sherman Pazner, a psychiatrist in private practice in Manhattan who is on the faculty of NYU.  They have two children, Evan, 30 and Toby, 25.  Dr. Zolla-Pazner and her husband are involved in the cultural life of New York, as founding members of the Helicon Chamber Music Foundation and supporters of the Third Street Music School.

Daniel Malamud

Dr. Malamud is Professor of Basic Sciences at the NYU College of Dentistry and Professor of Medicine at NYU College of Medicine, and Director of the HIV/AIDS Research Program (HARP) at NYU College of Dentistry.  His research interests include (1) Development of novel HIV inhibitors, (2) Role of the innate immune system in HIV/AIDS, and (3) Development of a saliva-based Point-of-Care diagnostic system for infectious agents.

Waseem Malick

Waseem Malick, Ph.D. is Vice President, Pharmaceutical and Analytical R&D Department, Hoffmann-La Roche Inc., Nutley, NJ, 07110. Dr. Malick received his B.S. (Pharmacy) from Panjab University, M.S. (Pharmaceutics) from Columbia University and Ph.D. (Pharmaceutics) from University of Michigan in 1976. He was Assistant Professor of Pharmaceutics at Wayne State University, Detroit from 1975-1978. In 1978, he started his industrial research career at American Hospital Supply Corporation and subsequently joined Hoffmann-La Roche, USA in 1981. He has been involved in preformulation, formulation, analytical and drug delivery research and currently is Global Head of Pharmaceutical & Analytical R&D at Roche. He has published extensively and has been very active in professional organizations. He has in the past served as the General Chairperson of the American Association of Pharmaceutical Scientists (AAPS) Eastern Regional Meeting and as the Chairperson of the Pharmaceutical Development Subsection of the Pharmaceutical Research and Manufacturers of America. He is an AAPS Fellow. Dr. Malick’s current responsibilities include global management and guidance of analytics, drug delivery research, preformulation, formulation and manufacture of clinical dosage forms, and package research.

Finley Austin

Dr. Austin is Director of US External R&D Policy at Roche and assists the company in addressing genomics and biomedical research issues affecting the pharmaceutical and diagnostic industries.

Dr. Austin received a B.S. in Psychology with honors in 1980 from Virginia Commonwealth University.  Prior to graduate school she worked in a clinical mental health setting, and neuropharmacology and neurophysiology research.  She was awarded a Ph.D. in Human Genetics in 1989 from the Medical College of Virginia at VCU.  Her graduate education included both course work and laboratory experience in human cytogenetics, quantitative genetics, and molecular genetics, and she received practical training in clinical genetics.  Dr. Austin then conducted postdoctoral research for four years in molecular genetics and pharmacology.

Her post-graduate career path has combined technology development, economics and policy. Prior to joining Roche, Dr. Austin competed for and was awarded an American Association for the Advancement of Science - Science, Engineering and Diplomacy Fellowship.  The fellowship, 1993 – 1995, involved working at the US Agency for International Development and on projects with the State Department in Washington DC.  She then accepted a position as Program Officer with the Burroughs Wellcome Fund (BWF), a private foundation supporting biomedical research in the U.S. and Canada.  In 1997, Dr. Austin was appointed Administrative Director of the Merck Genome Research Institute a not-for-profit corporation dedicated to supporting the development of new technologies to enhance functional genomics research. Dr. Austin left MGRI to become deputy editor of a start-up on-line journal Physiological Genomics.  She joined Roche in 1999 providing analysis and leading a cross-divisional team addressing numerous issues affecting R&D and innovation in the healthcare industry.

Kent Kirshenbaum

Dr. Kent Kirshenbaum’s research explores the interface between biopolymer and synthetic polymer chemistry. He is currently an Assistant Professor in the Department of Chemistry at New York University.

Kent studied Chemistry at Reed College in Portland, Oregon. His Bachelor’s degree thesis was supervised by Prof. Valerie Daggett, and utilized molecular dynamics simulations to investigate the conformation of the Alzheimer’s beta peptide. Kent then obtained his PhD in Pharmaceutical Chemistry at the University of California, San Francisco. Working with Prof. Ken Dill, Kent pursued the discovery of new folding codes in sequence-specific heteropolymer systems. During this time, Kent conducted his research on peptoid foldamers with the Bioorganic Chemistry group at Chiron Corporation, where he was a visiting scientist in the lab of Dr. Ronald Zuckermann. Kent was awarded an NIH post-doctoral fellowship to pursue studies in protein chemistry with Prof. David Tirrell at Caltech.

At New York University, Kent’s research has focused on investigating sequence-structure-function relationships in biomimetic oligomers. His work has been supported by the James D. Watson Investigator award and a CAREER award from the National Science Foundation. Kent’s scientific outreach efforts include co-founding the Experimental Cuisine Collective. He leads classes in Biochemistry and Bioorganic Chemistry at NYU.

Richard Willson

Richard Willson is Professor of Chemical & Biomolecular Engineering, Biochemistry, and Biomedical Engineering at the University of Houston, where his research focuses on biomolecular recognition and its applications in separations and diagnostics (  He received his B.S. (honors) and M.S. from Caltech, and his Ph.D. from MIT, and was a postdoctoral fellow in the MIT department of Biology before joining the University of Houston.  He is the recipient of a US Presidential Young Investigator Award and the ACS van Lanen Award, and is a fellow of the AIMBE.  He currently serves as President of the International Society for Molecular Recognition, which sponsors Affinity 2007.

Ron Breslow

Ronald Breslow has an A.B. in chemistry, an M. A. in Medical Science, and a Ph.D. in chemistry from Harvard, working with R. B. Woodward.  He spent a year with Lord Todd as a postdoctoral in Cambridge, England, before coming to Columbia University.  He is now Professor of Chemistry at Columbia, one of twelve University Professors, and a former Chairman of the Department.

Ronald Breslow was elected a member of the U.S. National Academy of Sciences in 1966; he is also a member of the American Academy of Arts and Sciences, the European Academy of Sciences, and the American Philosophical Society.  He is a Foreign Fellow of the Indian National Science Academy, an Honorary Member of the Korean Chemical Society, an Honorary Member of the Royal Society of Chemistry of Great Britain, a Foreign Member of the Royal Society of Britain, a Fellow of the World Innovation Foundation, an Honorary Member of the Chemical Society of Japan.  He is also an Honorary Professor of the University of Science and Technology of China.

He has been the Chairman of the Board of Scientific Advisors of the Alfred P. Sloan Foundation, and a member of the Board of Trustees of Rockefeller University. He is on the Editorial Board of a number of scientific journals, and has held over 200 named lectureships and visiting professorships.

In research he has synthesized the cyclopropenyl cation, the simplest aromatic system and the first aromatic compound prepared with other than six electrons in a ring.  He established the phenomenon of anti-aromaticity, and discovered the chemical mechanism used by thiamine (vitamin B-1) in biochemical reactions.  He has synthesized molecules that imitate enzymatic reactions, including the development of remote functionalization reactions and of artificial enzymes.  He has used the hydrophobic effect in organic synthesis and in mechanistic chemistry.   Recently he has developed a new group of cytodifferentiating agents with use in cancer chemotherapy 

His scientific awards include the American Chemical Society Award in Pure Chemistry, the Fresenius Award, the Baekeland Medal, the Centenary Medal, the Harrison Howe Award, the Remsen Prize, the Roussel Prize in Steroids, the James Flack Norris Prize, the Richards Medal, the Arthur C. Cope Award, the Kenner Award, the Nichols Medal, the National Academy of Sciences Award in Chemistry, the Allan Day Award, the Paracelsus Medal of the Swiss Chemical Society, and the U.S. National Medal of Science. He was named one of the top 75 contributors to the chemical enterprise in the past 75 years by Chemical & Engineering News, and won the Priestley Medal, the New York City Mayor's Award in Science, the Bader Award in Bioorganic Chemistry and the Esselen Award for Chemistry in the Public Interest.  In 2003 he received the Robert Welch Award in Chemistry, in 2004 he received the Willard Gibbs Award, and in 2006 he received the Othmer Gold Medal and the Paul Gassman Medal..

He has also received the Mark Van Doren Medal of Columbia University and the Columbia University Great Teacher Award. He was President of the American Chemical Society in 1996.